At the present time, multidose therapy with either erythromycin or co-trimoxazole is regarded as the treatment of choice for the disease in most endemic areas. However, recently, single-dose therapies with compounds exhibiting suitable pharmacokinetic properties and good in vitro activity against Haemophilus ducreyi have yielded cure rates in excess of 90%.
No takes yet. Share an insight, caveat, or question.
Dangor et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: